Quick Answer
SELLAS Life Sciences Group, Inc. reported Cash and Equivalents of $71.79 million for fiscal year 2025.
SELLAS Life Sciences Group, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $71.79M | +417.0% |
| 2024 | $13.89M | +448.9% |
| 2023 | $2.53M | -85.2% |
| 2022 | $17.12M | -19.8% |
| 2021 | $21.36M | -39.5% |
| 2020 | $35.30M | +385.1% |
| 2019 | $7.28M | +36.4% |
| 2018 | $5.34M | +130.1% |
| 2017 | $2.32M | -61.1% |
| 2016 | $5.96M | +326.8% |
| 2015 | $1.40M | -94.1% |
| 2014 | $23.65M | -50.5% |
| 2013 | $47.79M | +45.7% |
| 2012 | $32.81M | -31.3% |
| 2011 | $47.79M | +593.5% |
| 2010 | $6.89M | +21.2% |
| 2009 | $5.68M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $44.32M | +110.7% | +75.2% |
| June 30, 2025 | $25.30M | +176.6% | -10.9% |
| March 31, 2025 | $28.40M | +54.2% | +104.5% |
| December 31, 2024 | $13.89M | +448.9% | -34.0% |
| September 30, 2024 | $21.03M | +429.9% | +129.9% |
| June 30, 2024 | $9.15M | -33.8% | -50.3% |
| March 31, 2024 | $18.41M | -23.0% | +627.9% |
| December 31, 2023 | $2.53M | -85.2% | -36.3% |
- SELLAS Life Sciences Group, Inc. showed an increase of +417.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, SELLAS Life Sciences Group, Inc.’s cash and equivalents has grown by 1163.1% (from $5.68 million to $71.79 million).
- The most recent figure is from SELLAS Life Sciences Group, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: